KFAR SABA, Israel, Dec. 9, 2019 /PRNewswire/ — CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today that the external and independent Endpoint Adjudication Committee (EAC) performed the first Interim Analysis (IA) on the study data following enrollment of the 250th Subject into the study. The EAC reviewed …